We found that IBD activity was comparable in patients treated with anti-TNFα or not in the month following the third vaccine dose (p = 0.495 and p = 0.566 for HBI and SCCAI, respectively, using Pearson’s correlation). The gene discussed is TNF; the disease is inflammatory bowel disease.